Literature DB >> 22075486

Stage IV sarcoidosis: comparison of survival with the general population and causes of death.

A Nardi1, P-Y Brillet, P Letoumelin, F Girard, M Brauner, Y Uzunhan, J-M Naccache, D Valeyre, H Nunes.   

Abstract

The objectives of this study were to compare the survival of sarcoid patients with pulmonary fibrosis with that of the general population and to determine the causes of death and the incidence of evolutive complications. This retrospective cohort included 142 sarcoid patients in radiographic stage IV (74 males; mean ± SD age 48.1 ± 12 yrs). Their survival was compared with that of the general French population, matched for the year and age at diagnosis of stage IV disease, sex and length of follow-up. Expected survival probabilities were calculated year-by-year on the basis of probabilities provided by official demographic data for France. Survival curves were based on the Kaplan-Meier method and compared using the log-rank test. During the follow-up period (7.1 ± 4.8 yrs), pulmonary hypertension (PH) was observed in 29.7% of cases and aspergilloma in 11.3%. Long-term oxygen therapy was required in 12%. Survival was 84.1% at 10 yrs, which was worse than for the general population (p = 0.013). 16 (11.3%) patients died from the following causes: refractory PH (n = 5), chronic respiratory insufficiency (n = 4), acute respiratory insufficiency (n = 2), haemoptysis due to aspergilloma (n = 1), heart sarcoidosis (n = 1), nocardiosis (n = 1) and unknown causes (n = 2). Survival is significantly decreased in stage IV patients. 75% of fatalities are directly attributable to respiratory causes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22075486     DOI: 10.1183/09031936.00187410

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  35 in total

1.  Influence of pulmonary hypertension on survival in advanced lung disease.

Authors:  Don Hayes; Sylvester M Black; Joseph D Tobias; Heidi M Mansour; Bryan A Whitson
Journal:  Lung       Date:  2015-02-18       Impact factor: 2.584

Review 2.  Morbidity and mortality in sarcoidosis.

Authors:  Alicia K Gerke
Journal:  Curr Opin Pulm Med       Date:  2014-09       Impact factor: 3.155

Review 3.  [Pulmonary fibrosis in rheumatic diseases].

Authors:  D Grund; E Siegert
Journal:  Internist (Berl)       Date:  2018-09       Impact factor: 0.743

4.  The indications for the treatment of sarcoidosis: Wells Law.

Authors:  Robert P Baughman; Marc A Judson; Athol Wells
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

5.  Volumetric FDG PET analysis of global lung inflammation: new tool for precision medicine in pulmonary sarcoidosis?

Authors:  Human Adams; Rob van Rooij; Coline H M van Moorsel; Marcela Spee-Dropkova; Jan C Grutters; Ruth G Keijsers
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

Review 6.  The Clinical Features of Sarcoidosis: A Comprehensive Review.

Authors:  Marc A Judson
Journal:  Clin Rev Allergy Immunol       Date:  2015-08       Impact factor: 8.667

7.  The clinical and immunologic features of pulmonary fibrosis in sarcoidosis.

Authors:  Karen C Patterson; Kyle Hogarth; Aliya N Husain; Anne I Sperling; Timothy B Niewold
Journal:  Transl Res       Date:  2012-04-10       Impact factor: 7.012

8.  Refractory pulmonary sarcoidosis - proposal of a definition and recommendations for the diagnostic and therapeutic approach.

Authors:  Peter Korsten; Katharina Strohmayer; Robert P Baughman; Nadera J Sweiss
Journal:  Clin Pulm Med       Date:  2016-03

Review 9.  [Pulmonary fibrosis in rheumatic diseases].

Authors:  D Grund; E Siegert
Journal:  Z Rheumatol       Date:  2016-10       Impact factor: 1.372

Review 10.  From granuloma to fibrosis: sarcoidosis associated pulmonary fibrosis.

Authors:  Catherine A Bonham; Mary E Strek; Karen C Patterson
Journal:  Curr Opin Pulm Med       Date:  2016-09       Impact factor: 3.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.